Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 7/20 | 0.67 |
| ▸ | ACHE | P22303 | 3/20 | 0.65 |
| ▸ | APP | P05067 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM1A | O60341 | 2/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591063 | 0.81 | NPY5R (1.00) | NPY5RKMT2AMEN1ABCG2MAPK1 | |
| SCHEMBL2257787 | 0.80 | NPY5R (0.77) | NPY5RKDM4EKMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6039677 | 0.79 | NPY5R (0.96) | NPY5RKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL31060818 | 0.78 | ADORA3 (1.00) | ACHEAPPADORA3KDM4EMAPT | |
| SCHEMBL28212751 | 0.77 | ADORA3 (0.61) | ACHEAPPADORA3KDM4EMAPT | |
| SCHEMBL8890470 | 0.76 | NPY5R (0.70) | NPY5RKMT2AMEN1ABCG2KDM1A | |
| SCHEMBL3934069 | 0.76 | MKNK2 (0.49) | NPY5RACHEAPPADORA3KDM4E | |
| SCHEMBL8890945 | 0.76 | NPY5R (1.00) | NPY5RKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL8890734 | 0.76 | NPY5R (0.81) | NPY5RMAPTKMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8900357 | 0.75 | NPY5R (0.97) | NPY5RKDM4EMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108125959-B | Application of dimethoxy phenylamino acetamido quinazoline compound in preparation of drugs for treating leukemia | 浙江工业大学 | 2019-12-31 | — | — | CN | claimed |
| CN-108125959-B | Application of dimethoxy phenylamino acetamido quinazoline compound in preparation of drugs for treating leukemia | 浙江工业大学 | 2019-12-31 | — | — | CN | disclosed |
| CN-108125959-B | Application of dimethoxy phenylamino acetamido quinazoline compound in preparation of drugs for treating leukemia | 浙江工业大学 | 2019-12-31 | — | — | CN | disclosed |
| CN-108125959-B | Application of dimethoxy phenylamino acetamido quinazoline compound in preparation of drugs for treating leukemia | 浙江工业大学 | 2019-12-31 | — | — | CN | disclosed |
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | disclosed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | NPY5R 2541/4885ACHE 2924/4885APP 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.